Our website is made possible by displaying non-intrusive online advertisements to our visitors.
Please consider supporting us by disabling or pausing your ad blocker.
CHINA INFLUENZA RELATED STOCKS RISE AS FLU CASES RISE IN CHINA
HMPV cases surge in Malaysia following China outbreak; Government issues advisory
HMPV cases are now reportedly rising in China. In 2024, 327 HMPV cases were reported in the country, a 45% increase compared to 225 cases in 2023. This increase comes amidst reports of rising respiratory illnesses in other countries, including China.
Public health agencies across Europe are warning of the alarming spread of a new COVID strain that's threatening the continent. Called the XEC variant, the virus has already been detected in at least 11 European nations. It's also been identified beyond the EU, in countries that include Canada and the United States. While scientists are busily working to understand more about this latest COVID mutation, populations are being urged to get tested and request vaccinations.https://www.starsinsider.com/health/769174/new-covid-strain-threatens-europe-the-us-and-beyond
The US Centres for Medicare and Medicaid Services’ (CMS) proposal to include US-produced domestic nitrile gloves under its payment adjustment scheme from Jan 1, 2026, a decision that is expected to boost demand for US-made nitrile gloves, will benefit Supermax Corp Bhd.
The glovemaker, which recently commissioned its US plant, is said by CIMB Research to gain from the CMS’ proposed modification to include nitrile gloves under its payment adjustment scheme under its Medicare and Medicaid programmes in which buyers would be compensated for the additional costs of purchasing domestically manufactured gloves.
Found a 2nd Stock Prediction by Lily Lee who previously make a 100% accurate on MMC Corporation Berhad under YouTube channel ( MMC Corporation Berhad @ Super Stock )
By Lily Lee ;
SUPERMAX CORPORATION BERHAD Could Be a Super Stock in 2025
1. U.S. Expansion: Supermax's Texas facility, starting in January 2025, will strengthen domestic glove production in the U.S., reducing import reliance and boosting supply chain resilience.
2. Capacity Growth: Phase 1 adds 2.4 billion gloves annually, scaling to 19.2 billion across four phases, capturing a larger U.S. market share.
3. Favorable Trade Policies: U.S. tariffs on Chinese gloves (50% in 2025, 100% in 2026) create a supply gap that Supermax is well-positioned to fill.
4. Global Demand Recovery: A 15% annual increase in glove demand, driven by hygiene awareness, is expected to restore demand-supply balance.
5. Improved Financials: A 26% YoY revenue growth in Q1 FY2025 signals recovery, with U.S. operations set to drive profitability.
6. Strategic Expansion: Projects like Glove City and Supermax Business Park enhance long-term growth and production capacity.
7. Analyst Confidence: 'BUY' ratings with optimistic target prices reflect confidence in Supermax's growth strategy.
8. Enhanced ESG Compliance: Resolved labor issues and ESG improvements strengthen its reputation and appeal to investors.
9. Strong Cash Position: With RM1.16 billion cash and minimal debt, Supermax is well-equipped to fund expansions and overcome challenges.
10. Market Valuation: Resilient stock performance reflects investor confidence, with room for further appreciation due to strategic moves.
11. Asset Revaluation Potential: NTA at RM1.63, but asset revaluation (e.g., U.S. landbank) could exceed RM4.
12. Currency Advantage: A stronger USD benefits Supermax through increased export margins.
13. Based on current fund movement , foreign fund keep accumulating at Supermax stock (good signal)
Greatnews for glove stocks! Trump has just announced an additional 10% tariff on all Chinese products, raising the tariff on Chinese medical gloves to 60% from the current 50% under the Biden administration. This new tariff will take effect in January 2025.
#Bloomberg 季报赚钱